作为吉林省梅花鹿产业龙头企业，吉林敖东在"十五五"期间将进一步强化鹿茸产业的核心竞争力，以全 产业链闭环管理守护中药瑰宝的纯正与安全。公司自主培育的"敖东梅花鹿"作为国内首个以企业命名的 国家级梅花鹿品种，从遗传根源锁定了原料的纯正性与优良性状。在长白山核心产区，超350公顷的 GAP 标准化养殖基地持续扩容提质，梅花鹿存栏量稳定在近3000头，延续传统自然采食方式，确保鹿 茸原料的天然品质。为筑牢安全防线，公司累计投入超4600万元升级防疫设施，通过迁移职工家属区划 定隔离缓冲带等极致管控措施，自 2021年起连续保持布病与结核病零阳性纪录，实现鹿茸原料"全流程 闭环管理"，所有优质资源均锁定在自有体系内，从源头保障了中药材品质。 "全产业链布局不仅是品质'护城河'，也是抵御成本波动、践行社会责任的'稳定器'" 。吉林敖东表示， 公司将在"十五五"期间持续深化产业优势，以规模效应摊薄固定成本、增强产业链议价能力；企业将始 终以提升产品内在质量标准为核心，构建可持续的价值生态，用实际行动回馈消费者与投资者的信任。 依托优质鹿茸原料，吉林敖东在"十五五"期间将持续发力产品集群建设，以安神补脑液为核心的鹿系列 产 ...

Core Viewpoint - Jilin Aodong's stock price has shown fluctuations, with a recent decline of 2.04%, while the company has reported a significant increase in net profit year-on-year despite a decrease in revenue [1][2]. Group 1: Stock Performance - As of January 8, Jilin Aodong's stock price was 20.13 yuan per share, with a market capitalization of 24.073 billion yuan [1]. - The stock has increased by 3.07% year-to-date, with a 2.60% rise over the last five trading days and a 4.19% increase over the last 20 days, but has decreased by 1.00% over the last 60 days [1]. Group 2: Financial Performance - For the period from January to September 2025, Jilin Aodong reported operating revenue of 1.640 billion yuan, a year-on-year decrease of 14.10%, while net profit attributable to shareholders was 2.260 billion yuan, reflecting an increase of 81.70% [2]. Group 3: Shareholder Information - As of September 30, 2025, the number of shareholders for Jilin Aodong was 61,200, a decrease of 7.18% from the previous period, with an average of 19,456 circulating shares per shareholder, an increase of 7.73% [2]. - The company has distributed a total of 4.664 billion yuan in dividends since its A-share listing, with 1.881 billion yuan distributed over the last three years [3]. Group 4: Institutional Holdings - Among the top ten circulating shareholders as of September 30, 2025, the Southern CSI 500 ETF held 13.93 million shares, a decrease of 317,900 shares from the previous period, while the Hong Kong Central Clearing Limited held 11.82 million shares, down by 3.1962 million shares [3].

证券之星消息，1月6日中药板块较上一交易日上涨0.57%，吉林敖东领涨。当日上证指数报收于 4083.67，上涨1.5%。深证成指报收于14022.55，上涨1.4%。中药板块个股涨跌见下表： | 代码 | 名称 | | 主力净流入 (元) | 主力净占比 游资净流入 (元) | | 游资净占比 散户净流入 (元) | | 散户净占比 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 000538 | 云南白药 | | 4972.50万 | 9.71% | -1673.89万 | -3.27% | -3298.61万 | -6.44% | | 000650 仁和药业 | | | 4824.60万 | 7.72% | -2685.96万 | -4.30% | -2138.63万 | -3.42% | | 000623 | 吉林敖东 | | 4586.54万 | 7.83% | -2572.23万 | -4.39% | -2014.31万 | -3.44% | | 600332 | 白云山 | | 1648.82万 | 3.86% | -388 ...

Core Viewpoint - The Chinese traditional medicine industry is experiencing significant growth driven by policy support and increasing health demands, with a focus on balancing tradition and innovation [1] Group 1: Company Strategy - Jilin Aodong Pharmaceutical Group Co., Ltd. adopts a dual-driven strategy of "medicine health + financial capital" to modernize traditional Chinese medicine [1] - The company has established a robust capital collaborative network, holding 20.11% of Guangfa Securities and being a major shareholder in several pharmaceutical companies, which supports its main business [2][3] - Financial returns from investments in Guangfa Securities contributed 12.43 billion yuan and 17.49 billion yuan in 2023 and 2024 respectively, providing continuous financial support for the pharmaceutical business [3] Group 2: Financial Empowerment - The financial layout allows Jilin Aodong to maintain stable and abundant returns, which are reinvested into the pharmaceutical sector to alleviate the high risks and long cycles of research and development [3] - The company emphasizes a principle of "main business first, financial empowerment," ensuring that financial gains are directed back to support the core pharmaceutical operations [3] Group 3: Technological Innovation - Jilin Aodong places technological innovation at the core of its strategy, focusing on the research of key raw materials and advancing in fields like anti-aging and regenerative medicine [5] - The company has developed a closed-loop industrial chain around the breeding, processing, and quality control of deer antler, ensuring the quality and traceability of raw materials [5][6] - The implementation of modern technology in traditional practices is seen as essential for unlocking the core value of traditional Chinese medicine [5][6] Group 4: Industry Development - The modernization of traditional Chinese medicine is supported by national policies aimed at enhancing quality, digital transformation, and new drug development [4] - Jilin Aodong aims to reshape production factors through technological innovation, transitioning from resource-dependent to innovation-driven models [6] - The company is committed to continuous investment in research and development, enhancing its intelligent layout across the entire industrial chain, and maintaining its heritage as a time-honored brand [7]

中医药创新向来具有高投入、长周期、高风险的显著特征。从道地药材的良种选育、生态种植，到炮制工艺的数字化升 级，再到经典名方的二次开发与临床转化，全链条均需持续性资金投入，且始终面临技术攻关与市场落地的双重不确定性。若 单纯依赖企业经营利润的滚动投入，极易陷入抗风险能力不足的困境，难以支撑重大基础研究与核心创新项目的推进。 本报记者 马宇薇 在政策持续加码与健康需求不断升级的双重驱动下，我国中医药产业规模不断扩大，迎来高质量发展黄金期。在此背景 下，行业发展的核心命题愈发清晰：如何平衡传承与创新？如何让中华老字号焕发新生？这考验着每一家中医药企业的战略定 力。 作为深耕中医药领域的标杆企业，吉林敖东药业集团股份有限公司（以下简称"吉林敖东"）以"医药健康+金融资本"双轮 驱动战略为引领，走出了一条彰显特色产业优势、深植创新基因的中医药现代化发展之路。 近日，吉林敖东董事长李秀林接受《证券日报》记者专访，深度解读企业在双轮驱动、科技创新及中医药现代化方面的布 局与思考。 构建资本协同网络 近年来，随着国家对中医药产业的高度重视，一系列扶持政策密集落地，涵盖质量提升、数智化转型、新药研发等全链 条，全方位推动中医药 ...

r 228000 ...

吉林敖东相关负责人日前在接受中国证券报记者采访时表示，当前，中医药产业处于重要发展机遇期。 吉林敖东将紧紧抓住政策和市场机遇，充分发挥长白山"自然宝库"的资源优势和数十年梅花鹿养殖的经 验优势，大力推进中医药传承创新，实施"医药健康+金融资本"双轮驱动发展战略，为高风险、长周期 的医药研发构筑坚实的财务后盾，让金融"活水"精准"灌溉"医药主业，推动公司在传承中创新、在创新 中发展，走出一条特色中医药产业强基之路，让"老字号"焕发勃勃生机。 "面对严峻挑战，我们持续提升产品内在质量标准，增加科技专利附加值，确保市场零售价格稳定，建 立可持续的价值生态。"吉林敖东总经理郭淑芹说。 这份坚持赢得了市场回报与信任。以"国民产品"敖东安神补脑液为例，上市以来，产品累计销量近百亿 支，年收入最高超7亿元，占国内同类产品市场70%以上份额，成为细分领域绝对龙头。 ● 本报记者 宋维东 做强中医药产业 如今闻名全国的药企吉林敖东，最初是从一家国营鹿场起步的。在外人看来，养鹿与制药"八竿子打不 着"，但实际上梅花鹿养殖不仅奠定了吉林敖东发展的根基，更为公司做强中医药产业提供了巨大助 力。 "鹿茸是传统中药瑰宝。公司坚守长白山核 ...

Group 1 - The flu epidemic in China is at a high level, primarily driven by the H3N2 strain, with increased transmission risk due to upcoming population movements during the New Year holiday [1] - Demand for antiviral and symptomatic medications has surged, with a reported over 500% increase in flu-related drug purchases on Alibaba Health and over 100% increase in orders for traditional Chinese medicine on Meituan [1] - The pharmaceutical industry is responding effectively across the supply chain, from vaccine production to drug distribution, indicating a well-coordinated effort to manage the public health challenge [1][2] Group 2 - Vaccine companies are ramping up production, with Hualan Vaccine reporting 55 batches of flu vaccine issued since November, reflecting increased public willingness to get vaccinated [2] - Diagnostic companies like Dian Diagnostics and Kingmed Diagnostics are seeing increased business, supporting the trend of testing before treatment, which enhances rational drug use [2] - The treatment landscape is diversifying, with both chemical and traditional Chinese medicines being utilized, indicating a shift in market dynamics [3][5] Group 3 - Traditional Chinese medicine is gaining traction, with companies like China Resources Sanjiu and Kangyuan Pharmaceutical seeing strong growth in their antiviral product lines [5] - The distribution sector is crucial, with companies like Yiyigou ensuring rapid delivery of essential medications during peak demand periods [5] - The clinical relevance of traditional Chinese medicine is increasing, supported by government policies that endorse its use in flu treatment, leading to a rise in evidence-based research [6][9] Group 4 - Companies are focusing on clinical research to validate the efficacy of traditional Chinese medicines, with Kangyuan Pharmaceutical conducting head-to-head trials against conventional drugs [7][9] - The competitive landscape in the respiratory system traditional Chinese medicine market is diverse, with companies like China Resources Sanjiu and Yiling Pharmaceutical leveraging brand strength and market recognition [9] - As the industry moves towards evidence-based medicine, companies with strong research capabilities and clinical data are likely to capture more market opportunities [9]

| 权益类证券大宗交易(协议交易) | | | | | | | 团 下载 | | --- | --- | --- | --- | --- | --- | --- | --- | | 交易日期 | 证券代码 | 证券简称 | 成交价格 (元) | 成交量 (万股/万份) | 成交金额 (万元) | 买方营业部 | 卖方营业部 | | 2025-12-29 | 000623 | 吉林敖东 | 18.68 | 18.90 | | 353.05 招商证券股份有限 | 中山证券有限责任 | | | | | | | | 公司天津友谊北路 | 公司湖北分公司 | | | | | | | | 证券营业部 | | 12月29日，吉林敖东大宗交易成交18.9万股，成交额353.05万元，占当日总成交额的1.81%，成交价 18.68元，较市场收盘价19.62元折价4.79%。 ...

本次药品捐赠聚焦当地群众卫生健康需求，涵盖了包括对乙酰氨基酚泡腾片、氨咖黄敏胶囊、复方氨酚烷胺片、复方金银 花颗粒在内的4类急需常用药品，总价值人民币59.49万元。这些药品将精准发放至1147户农牧民家庭，有效补充基层医疗卫生 资源，为当地村民的健康保驾护航。 在为基层群众送去健康保障的同时，吉林敖东也始终锚定中医药传承创新的发展方向，稳步推进产业升级。在中医药传承 创新的浪潮中，吉林敖东以科技创新为核心引擎，以标准建设为重要抓手，走出了一条兼具传统特色与现代气息的中医药产业 发展之路。 在科技创新层面，吉林敖东聚焦中药材核心物质基础研究，布局抗衰与再生医学前沿领域，推动中医药从"经验传 承"向"科学解码"跨越。吉林敖东深度挖掘传统中药材的现代科研价值，其相关研究证实，部分中药材活性成分在抗衰、神经 保护、骨骼修复等方面展现出巨大潜力。依托这些研究成果，吉林敖东成功斩获两项重磅发明专利，推动核心产品从传统功效 定位，升级至前沿赛道，精准对接高品质健康消费需求。 同时，吉林敖东以新质生产力赋能中医药全产业链智能化升级。在产业链前端，运用分子辅助育种等生物技术优化药材种 源性状，引入智能化管理系统，实现种植、养 ...